Introduction: Patients with diabetic macular edema (DME), a chronic, vision-limiting ±3.6)]. Conclusion: In a real-world setting, 0.2 lg/day FAc implant in both eyes was a feasible, effective choice for patients with severe bilateral DME, without notable increases in IOP.
condition, may be insufficiently responsive to standard-of-care anti-vascular endothelial growth factor (VEGF) and/or laser therapies. 
INTRODUCTION
Diabetic retinopathy (DR) is a visual complication that presents in around 35% of patients with diabetes [1] . A further visual complication manifesting in 6.8% of patients with DR is diabetic macular edema (DME), a chronic condition that results in significant reduction in vision and blindness in the working-age population [1] . DME can be unilateral or bilateral, with bilateral DME presenting in approximately 33-46% of patients with DME [2, 3] . Due to its chronic nature and persistence, DME can be difficult to manage, and without treatment nearly half of all patients who develop DME will lose two or more lines of visual acuity (VA) within 2 years [4, 5] .
Historically, the standard of care for DME was laser therapy; however, vision gain following such treatment was limited [6] . More recently, several prospective randomized clinical trials have shown significant gains in VA in patients with DME following treatment with anti-vascular endothelial growth factor (VEGF) agents, resulting in a shift toward anti-VEGF treatment as the preferred standard of care and first line of treatment [6] [7] [8] [9] . Despite promising efficacy, however, results from the RIDE (ClinicalTrials.gov identifier, NCT00473382) and RISE (ClinicalTrials.gov identifier, NCT00473330) trials investigating the anti-VEGF agent, ranibizumab, found that patients who crossed over from sham to ranibizumab at 24 months were notably less responsive to treatment. These data are indicative of a subgroup of patients with longer-term chronic DME who may be insufficiently responsive to intermittent therapies such as the injection of anti-VEGF [8, 9] .
Chronic DME is thought to be associated with a more inflammatory state following a shift in the expression of numerous inflammatory cytokines and VEGF-independent pathways responsible for its pathogenesis [10] . Consequently, chronic DME may require broader spectrum treatments such as corticosteroids, which have anti-inflammatory and angiostatic effects [11] [12] [13] . 
RESULTS

Patients
Overall, six patients with bilateral chronic DME received 0.2 lg/day FAc implant in both eyes (12 eyes 
DISCUSSION
This study evaluated the bilateral injection of 0.2 lg/day FAc implant in six patients with DME in both eyes in the real-world setting. All eyes had received C1 macular laser treatment and C3 ranibizumab injections and were deemed insufficiently responsive to these treatments. Ten eyes had also received C1 IVTA injection prior to 0. [19] and 34% gained C15 letters [16] . Four patients had achieved or maintained driving vision and there was a notable reduction in CRT in all eyes with a baseline CRT [600 lm. This is an important outcome in the management of DME progression, as prolonged edema results in irreversible damage and permanent vision loss, emphasizing the need for early intervention [20] . Further, minimal increases in IOP were observed and no patients needed to initiate ranibizumab found that patients with chronic DME may become refractory to anti-VEGF therapy once DME disease progresses [9] . If, as some evidence suggests [10] , this is associated with a more complex inflammatory cytokine state, treatment with corticosteroids may be appropriate at an earlier stage in patients with chronic DME.
In the FAME trials, the sustained and localized release of 0.2 lg/day FAc implant resulted in improved visual and anatomical outcomes that were maintained for up to 36 months [16] . However, the proportion of patients with chronic DMO that achieved driving vision following 0.2 lg/day FAc implant was reduced in patients with lower baseline VA, highlighting the importance of early treatment for optimal visual outcomes [21] . Consequently, in patients with bilateral DME, treatment of both eyes with 0.2 lg/day FAc implant may be beneficial and, as it is not contraindicated, should be considered.
Limitations
The main study limitations relate to the retrospective nature of the study and the limited study size ( 
